Dendreon Corporation Cancer Drugs Clinical Pipeline Insight

Reports
Published
Number of pages
27

For Wire/Bank transfer, contact us at info@pnspharma.com

Electronic Access - Single User License
$500
CD-ROM Mail Delivery
$800
Hard Copy Mail Delivery
$800
Electronic Access - Multi-User License
$1000

“Dendreon Corporation - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Dendreon Corporation. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there is “1” cancer drug in clinical pipeline. There is 1 cancer drug by Dendreon Corporation which is commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Dendreon Corporation - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. Dendreon Corporation

  1.1 Business Overview

  1.2 Dendreon Corporation Cancer Pipeline Overview

 

2. Dendreon Corporation Cancer Drugs in Phase-II

  2.1 Lapuleucel-T

 

3. Marketed Cancer Drugs by Dendreon

  3.1 Sipuleucel (Provenge)

 

4. Discontinued in Cancer Drugs in Clinical Pipeline

  4.1 Recombinant NAPc2

  4.2 APC 8020

  4.3 CTL 8004

  4.4 Matriptase Inhibitors - Amgen/Dendreon

  4.5 Endotheliase Inhibitors - Dendreon/Dyax

  4.6 DN 1924

  4.7 Cancer Vaccine NY-ESO-1 – Dendreon

  4.8 Protease Activated Cancer Therapy – Dendreon

  4.9 Urokinase Plasminogen Activator Inhibitors – Dendreon

 

5. Suspended in Cancer Drugs in Clinical Pipeline

  5.1 D 3263

  5.2 Anti-CA9 Vaccine – Dendreon

  5.3 Anti-CEA Vaccine – Dendreon

Figure 1-1: Dendreon Corporation Cancer Pipeline by Phase (%)

Figure 1-2: Dendreon Corporation Cancer Pipeline by Phase (Number)

Figure 1-3: Dendreon Corporation Cancer Drugs Discontinued & Suspended in Clinical Pipeline by Phase (%)

Figure 1-4: Dendreon Corporation Cancer Drugs Discontinued & Suspended in Clinical Pipeline by Phase (Number)